Welcome Message

Dear Speakers, Delegates, Exhibitors & Sponsors,

It's my great pleasure to invite you on behalf of the Pharmacoepidemiology Congress-2024’s Organizing Committee, and to invite you to attend “International Conference on Pharmacoepidemiology and Clinical Research” to be hosted in Vancouver, Canada, on November 20-21, 2024.

The Pharmacoepidemiology Congress-2024 Conference is an International conference of 2 days, providing the most up-to-date information, research, guidance and policy discussion for professionals in the Clinical Research and Medical field. It's your opportunity to socialize and learn from friends and colleagues worldwide while having a great time.

There will be well-known speakers from across the world who will discuss, analyze, and debate important new discoveries and scientific achievements that will have an impact on the future of medicine and related professions.

We very much look forward seeing you in Vancouver, Canada, on November 20-21, 2024. We hope you'll join us to make this conference a memorable event!

Thanks & Regards

Organizing Committee

About Conference

 

Session & Tracks

Conference Series Ltd is delighted to extend our warm welcome to you all to participate in the 14th International Conference on Pharmacoepidemiology and Clinical research,, scheduled  during November 20-21,2024. at Vancouver, Canada. , with the theme "Impact of Telemedicine on Drug Safety Monitoring in Rural Populations”.

Experts Meeting to join the Global scientific influencers from  Asia, Middleeast, Europe, USA(America) and Africa at Pharmacoepidemiology and Clinical research Congress, organised at November 20-21,2024. at Vancouver, Canada. with a main theme “Focused on all research activities for optimal use and safety of medication”.

Pharmacoepidemiology Congress includes a wide range of Keynote presentations, Oral talks, Poster presentations, Symposia, Workshops, Exhibitions and extensive networking and B2B interactions.

 Track 1: Pharmacoepidemiology and Clinical Research

Pharmacoepidemiology is an extensive area of science which involves uses and effects of drugs in larger arena of population. Pharmacoepidemiology is a bridge of science which connects both pharmacology and epidemiology enhancing the informative study on topics apparently related to Pharmacoepidemiology, Pharmacokinetics, Adverse drug reactions, Public health, Epidemiologic methods, Medication adherence and Drug safety, Pharmacovigilance, effects of genetic variation on drug effect, duration-response relationships, clinical effects of drug-drug interactions. This topic serves as a best way for Researchers to express their findings as research presentations on an array of Pharmacoepidemiology and Drug Safety. The main aim of Pharmacoepidemiology within the industry is to protect patients from unnecessary medication hazards by identifying the adverse effects, elucidating pre-disposing factors, refuting false safety signals and quantifying risk in relation to benefit. Clinical research  is the branch of science that involves the use of various medications, clinical therapeutics, medical and clinical devices, equipment and medical products for diagnosis and treatment of human disorders, diseases and patient safety.

Related Associations or Societies:

International Society for Pharmacoepidemiology, Center for Drug Safety and Effectiveness,  Center for Public Health and Human Rights, Center  for Health Services  and Outcomes Research, International Pharmaceutical Federation, International Society of Pharmacovigilance .

Track 2: Pharmacotherapy and Drug Safety

Pharmacotherapy also known as drug therapy is the use of a medical therapies (Surgical, Chemotherapy, Physical therapy, Radiation therapy) to treat disease. Drugs interact with receptors or enzymes present in cells, which promote healthy functioning and shave or cure illness. Drug Safety refers to the pharmacological science that ensures safety and is related to the collection, detection, assessment, monitoring, and prevention of adverse drug effects with pharmaceutical products. Safety monitoring in clinical trials involves the collection of adverse events, laboratory investigations including the planning, execution, data analysis and reporting of the safety information and details of the clinical examination of patients.

Related Associations or Societies:

International Society for Pharmacoepidemiology, Center for Drug Safety and Effectiveness,  Center for Public Health and Human Rights, Center  for Health Services  and Outcomes Research, International Pharmaceutical Federation, International Society of Pharmacovigilance .

Track 3: Action of Drugs

Action of Drugs also known Pharmacodynamics. It refers to the study of Drugs, its biochemical, physiologic effects, the mechanisms and its action on the body or on microorganisms and other parasites within or on the body. It deals with drug action, which is the initial consequence of a drug-receptor interaction, and drug effect, which refers to the subsequent effects. The drug action of digoxin, for example: The inhibition of membrane Na+/K+-ATPase; the drug effect is augmentation of cardiac contractility. In this example, the clinical response may comprise of improved exercise tolerance.

Related Associations or Societies:

International Society for Pharmacoepidemiology, Center for Drug Safety and Effectiveness,  Center for Public Health and Human Rights, Center  for Health Services  and Outcomes Research, International Pharmaceutical Federation, International Society of Pharmacovigilance .

Track 4: Clinical Research

Clinical research  is the branch of science that involves the use of various medications, clinical therapeutics, medical and clinical devices, equipment and medical products for diagnosis and treatment of human disorders, diseases and patient safety.

Related Associations or Societies:

International Society for Pharmacoepidemiology, Center for Drug Safety and Effectiveness,  Center for Public Health and Human Rights, Center  for Health Services  and Outcomes Research, International Pharmaceutical Federation, International Society of Pharmacovigilance .

Track 5: Clinical Trials

Clinical trials describe the distinct procedures followed in development of new drugs. These are the characteristic studies intended for the treatment of behavioural symptoms among the medical intervention and a health outcome. Clinical trials comprise patient data, disease mechanisms, therapeutic interventions, epidemiology, clinical medicine, preclinical and clinical pharmacology, immunology, toxicological studies. Clinical trials consist of experimental clinical trials scrutinizes the new treatment replacing the placebo or existing alternative treatments and  safety methodology using data from observation of patients treated in clinical. Clinical data is the key feature translating basic research into medical care. The perfect conclusion of clinical trials is minimize risks, extend benefits and optimal use of an intervention of therapeutic drugs.

Related Associations or Societies:

Society for Clinical Trials, Association of Clinical Research, The Society of Clinical Research Associates, Clinical Research Society, American Association of Pharmaceutical Scientists, Association of British Pharmaceutical Industry .

Track 6: Pharmacology

Pharmacology  is the study of interaction between substances with living organisms to produce a change in function. It deals with the research, discovery, and characterization of chemicals that show biological effects and the illumination of cellular and organism function in relation to these chemicals. If substances have medicinal properties, they are defined as pharmaceuticals. The Pharmacology encompasses mechanisms of drug action, drug composition and properties, interactions, toxicology, therapies, medical applications, and anti pathogenic capabilities.

Related Associations or Societies:

International Society for Pharmacoepidemiology, Center for Drug Safety and Effectiveness,  Center for Public Health and Human Rights, Center  for Health Services  and Outcomes Research, International Pharmaceutical Federation, International Society of Pharmacovigilance .

Track 7: Pharmacoepidemiology and Public Health

Pharmacoepidemiology is an extensive area of science which involves uses and effects of drugs in larger arena of population. Pharmacoepidemiology is a bridge of science which connects both pharmacology and epidemiology enhancing the informative study on topics apparently related to Pharmacoepidemiology, Pharmacokinetics, Adverse drug reactions, Public health, Epidemiologic methods, Medication adherence and Drug safety, Pharmacovigilance, effects of genetic variation on drug effect, duration-response relationships, clinical effects of drug-drug interactions. This topic serves as a best way for Researchers to express their findings as research presentations on an array of Pharmacoepidemiology and Drug Safety. Public health describes “the science and art of preventing disease, lengthening life and further human health through methodized efforts and informed choices of society, organizations, public and private, communities and individuals." It is concerned with threats to health based on population health analysis .The focus of public health intercession is to promote health and quality of life through obstruction and treatment of disease and other physical and mental health conditions. This is done through supervision of cases and health indicators, and through advancement of healthy behaviours

Related Associations or Societies:

Society for Clinical Trials  Association of Clinical Research  The Society of Clinical Research Associates  Clinical Research Society  American Association of Pharmaceutical Scientists Association of British Pharmaceutical Industry  International Society for Pharmacoepidemiology

Track 8: Genetic Epidemiology

Genetic epidemiology refers to “the role of genetic factors and genetic variations for determining health, disease in families and in populations and the interplay of such genetic factors with environmental factors. Genetic epidemiology seeks to derive a statistical and quantitative analysis of how genetics work in huge groups.

Related Associations or Societies:

International Society for Pharmacoepidemiology Center for Drug Safety and Effectiveness Center for Public Health and Human Rights Center  for Health Services  and Outcomes Research  International Pharmaceutical Federation   International Society of Pharmacovigilance

Track 9: Drug Discovery and Drug Development

Pharma compounds which were developed in the olden days were discovered and developed either by identifying the active ingredient from traditional remedies or by serendipitous discovery. But the advancements in the science and technology has made the job easier by controlling them at molecular and physiological level. During the phase of drug discovery main reason for the disease is identified and the possible pharmacological molecules are discovered. Later effect of that molecule on animals, humans are tested and if further improvements to be made, are performed. This involves many steps like identifying the reason for disease, lead identification, lead development, lead optimization, testing, and marketing.

Related Associations or Societies:

Society for Clinical Trials  Association of Clinical Research  The Society of Clinical Research Associates  Clinical Research Society  American Association of Pharmaceutical Scientists Association of British Pharmaceutical Industry  International Society for Pharmacoepidemiology

Track 10: Clinical Data Management

Databases contain professional assessment of the potential of drugs and permit the risk- profit analysis of medicinal products taking under consideration new and emerging information, within the context of additive data. These databases offer programming of alerts for fast cases, follow-up cases and reports submission to fulfil regulative timeline compliance. Data sources of pharmacoepidemiological databases are CPRD (Clinical Practice Research Data link), IMS Health Disease Analyser databases, PHARMO, Vigibase and Eudravigilance. Pharmacoepidemiology research studies may involve either data collected prospectively for the purpose of the particular study i.e. primary data, or data that were already collected for another purpose – as part of administrative records or patient health care , which is called secondary data.

Related Associations or Societies:

International Society for Pharmacoepidemiology Center for Drug Safety and Effectiveness Center for Public Health and Human Rights Center  for Health Services  and Outcomes Research  International Pharmaceutical Federation   International Society of Pharmacovigilance

Track 11: Clinical Pharmacy

Clinical Pharmacy and Pharmacy Practice involves developing the professional roles of pharmacists and is the order of drug store which includes adding to the expert parts of drug specialists. It includes Disease-state management, Clinical drug interventions, Pharmacy professional development and pharmaceutical care, pharmaceutical compounding and health psychology, patient care, drug abuse prevention, prevention of drug interactions or minimisation of adverse events and drug incompatibility and community pharmacy.

Related Associations or Societies:

Society for Clinical Trials  Association of Clinical Research  The Society of Clinical Research Associates  Clinical Research Society  American Association of Pharmaceutical Scientists Association of British Pharmaceutical Industry  International Society for Pharmacoepidemiology

Track 12: Pharmacovigilance and its Significance

Pharmacovigilance plays a key role in all phases of clinical trials, including the planning, execution, data analysis and reporting of safety information and also bears an important responsibility for the expedited reporting of individual cases and safety updates required for regulatory authorities. The concept of Pharmacovigilance and its Significance enhances the impact of healthcare management on patient welfare and public health. Pharmacovigilance legislation gives an outlook on the rules and regulations to follow in Pharmacovigilance practice. The Role of Pharma industries in the improvement of Pharmacovigilance system is very crucial to maintain the safety data, detection and evaluation of drug safety signals through manual and medical devices reporting. Pharmacovigilance scope also deals as Eco Pharmacovigilance (EPV), Pharmacoenvironmentology and Pharmacovigilance in herbal medicines. In addition, data from observational epidemiological studies are playing an increasingly important role.

Related Associations or Societies:

International Society for Pharmacoepidemiology Center for Drug Safety and Effectiveness Center for Public Health and Human Rights Center  for Health Services  and Outcomes Research  International Pharmaceutical Federation   International Society of Pharmacovigilance .

Track 13: Risk Management

Pharma Risk Management was designed as a set of Pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks of medicinal and therapeutic products including the assessment of the effectiveness of their clinical reactions, interventions and combination therapies. Drug industry need to promote companies in Pharmacovigilance practice to use information technology and provide efficient software to implement the risk minimisation plans in drug development and manufacture. Pharmaceutical risk management monitors unlicensed, off labels and orphan drugs ,risk management labelling, regulatory decisions, legal protection, intellectual property, enforcement, marketing, and company reputation.

Related Associations or Societies:

International Society for Pharmacoepidemiology Center for Drug Safety and Effectiveness Center for Public Health and Human Rights Center  for Health Services  and Outcomes Research  International Pharmaceutical Federation   International Society of Pharmacovigilance

Track 14: Regulatory Affairs

Regulatory affairs is developed to protect public health by controlling the safety and efficacy of medical devices and pharmaceutical drug products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines. Regulatory affairs (RA), also called government affairs, are a profession within regulated industries, such as pharmaceuticals, medical devices, energy, banking, telecom etc.

Related Associations or Societies:

Society for Clinical Trials  Association of Clinical Research  The Society of Clinical Research Associates  Clinical Research Society  American Association of Pharmaceutical Scientists Association of British Pharmaceutical Industry  International Society for Pharmacoepidemiology

Track 15: Innovations in Clinical Trial Design

The field of clinical trial design has undergone significant evolution in recent years, driven by the growing need for more efficient, flexible, and patient-centered approaches to drug and therapeutic development.This track focuses on cutting-edge advancements in clinical trial methodologies that aim to accelerate the research process while maintaining high standards of scientific rigor and patient safety.

Related Associations or Societies:

European Society for Clinical Trials in Oncology (ESCTO) International Clinical Trials Methodology Conference (ICTMC) International Biometric Society (IBS) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Society for Biostatistics in Clinical Trials (SBCT)

Track 16: Global Health and Pharmacoepidemiology

Global health and pharmacoepidemiology intersect at the critical point of addressing the safe and effective use of medications across diverse populations worldwide. This track focuses on the application of pharmacoepidemiological principles to global health challenges, with an emphasis on drug safety, access, utilization, and effectiveness in low- and middle-income countries (LMICs) and other under-resourced settings.

Related Associations or Societies:

World Health Organization (WHO) International Society for Pharmacoepidemiology (ISPE) Global Health Council (GHC) International Union Against Tuberculosis and Lung Disease (The Union) International Network for Rational Use of Drugs (INRUD)

Track 17: Patient-Centered Approaches in Clinical Research

Patient-centered approaches in clinical research represent a shift from traditional investigator-driven studies to a model where patients play a central role in the research process. This track focuses on the growing emphasis on integrating patient perspectives, needs, and experiences into clinical trial design, conduct, and outcomes assessment to improve the relevance, quality, and impact of research on patient health.

Related Associations or Societies:

Patient-Centered Outcomes Research Institute (PCORI) International Society for Quality of Life Research (ISOQOL) Society for Participatory Medicine (SPM) European Patients’ Academy (EUPATI) National Health Council (NHC)

Track 18: Advanced Methodologies in Pharmacoepidemiology

This track focuses on innovative techniques enhancing the study of drug safety and effectiveness. Key areas include machine learning for pattern detection, propensity score matching to mitigate bias, and causal inference methods  for better understanding drug outcomes. It also covers Bayesian statistics for dynamic evidence updates and multi-database studies for comprehensive global insights. These advanced methodologies help navigate complexities in real-world data, improving the precision and reliability of pharmacoepidemiological research and ultimately enhancing medication safety and efficacy on a population level.

Related Associations or Societies:

International Society for Pharmacoepidemiology (ISPE) Society for Research on Epidemiology (SRE) International Biometric Society (IBS) American Statistical Association (ASA) European Society for Clinical Pharmacology and Therapeutics (ESCPT) Society for Clinical Trials (SCT)

Track 19: Biomarkers and Precision Medicine

It delves into the transformative role of biomarkers in precision medicine, which aims to tailor treatments based on individual genetic, environmental, and lifestyle factors. It covers the discovery, validation, and application of biomarkers for early disease detection, prognosis, and personalized treatment strategies. The track explores how biomarkers facilitate targeted drug development, optimize patient stratification, and improve clinical outcomes. Key discussions include integrating biomarkers into clinical practice, overcoming regulatory and technical challenges, and advancing personalized therapy approaches to enhance treatment efficacy and patient care.

Related Associations or Societies:

American Association for Cancer Research (AACR) American Society of Clinical Oncology (ASCO) European Society for Medical Oncology (ESMO) American Society for Human Genetics (ASHG) International Society for the Advancement of Cytometry (ISAC)

Track 20: Decentralized and Virtual Clinical Trials

This track examines the innovative shift towards decentralized and virtual clinical trials, leveraging technology to conduct research remotely and enhance patient accessibility. Key topics include the use of telemedicine, mobile health apps, and wearable devices to collect data and monitor patient outcomes outside traditional clinical settings. Discussions cover the benefits of reducing patient burden, improving recruitment and retention, and addressing logistical challenges. The track also explores regulatory considerations, data security, and the integration of virtual tools into trial designs to streamline processes and increase efficiency while maintaining high standards of data integrity and participant safety.

Related Associations or Societies:

Clinical Trials Transformation Initiative (CTTI) Society for Clinical Research Sites (SCRS) Drug Information Association (DIA) Association for Clinical Research Professionals (ACRP) e Clinical Solutions Decentralized Trials and Research Alliance (DTRA)

Market analysis

The global market for pharmacoepidemiology and clinical research is diverse, with varying levels of investment, research activity, and market dynamics across different countries. This analysis provides a detailed overview of key regions and countries driving the growth in these fields.

1. North America

       United States (USA):

• Market Size: Approximately $50 billion.
• Overview: The USA leads the global market for pharmacoepidemiology and clinical research. This dominance is driven by substantial investments in research and development, a highly regulated environment, and the presence of numerous pharmaceutical and biotech companies. The US boasts a robust infrastructure for conducting clinical trials, including a vast network of clinical research organizations (CROs), academic institutions, and healthcare facilities. Advanced methodologies such as real-world evidence (RWE) and precision medicine are widely implemented, supported by government agencies like the FDA and NIH. The USA also hosts a large number of clinical trials due to its diverse population and high patient recruitment rates.

       Canada:

• Market Size: Approximately $8 billion.
• Overview: Canada is an emerging player in pharmacoepidemiology and clinical research, with significant growth in research collaborations and clinical trial activities. The Canadian government supports research through various funding agencies, including CIHR and NSERC. Canada’s strengths include its strong healthcare system, high-quality data collection capabilities, and progressive research policies. The country is also gaining attention for its contributions to drug safety studies and health outcome research.

2. Europe

       Germany:

• Market Size: Approximately $12 billion.
• Overview: Germany is a major hub for pharmacoepidemiology and clinical research in Europe. It benefits from a strong pharmaceutical industry, extensive research networks, and a rigorous regulatory framework. Germany is known for its focus on drug safety, efficacy studies, and health technology assessments. Institutions like the Federal Institute for Drugs and Medical Devices (BfArM) and numerous academic centers contribute to the country’s robust research environment.

      United Kingdom (UK):

• Market Size: Approximately $10 billion.
• Overview: The UK has a well-established clinical research infrastructure, supported by organizations like the National Institute for Health Research (NIHR) and a strong academic base. The UK’s focus is on both early-phase and late-phase clinical trials, with significant investments in pharmacoepidemiology research. The NHS provides a unique platform for large-scale studies and real-world evidence generation. Post-Brexit, the UK continues to be a key player in global clinical research despite regulatory changes.

      France:

• Market Size: Approximately $9 billion.
• Overview: France is active in pharmacoepidemiology, with a focus on drug safety and effectiveness studies. The country’s research landscape is supported by institutions such as the French National Agency for Medicines and Health Products Safety (ANSM) and a strong network of research hospitals. France is known for its comprehensive health data systems and its contributions to studies on chronic diseases and rare conditions.

      Italy:

• Market Size: Approximately $7 billion.
• Overview: Italy has a growing clinical research sector, with increasing emphasis on innovative trial designs and patient-centered approaches. The Italian Medicines Agency (AIFA) oversees drug safety and efficacy studies, and Italy’s academic institutions and CROs play a significant role in the research landscape. The country is also investing in digital health technologies and data-driven research.

3. Asia-Pacific

      China:

• Market Size: Approximately $20 billion.
• Overview: China’s market for pharmacoepidemiology and clinical research is expanding rapidly due to its large population and growing investments in healthcare infrastructure. The country is increasing its focus on drug safety and efficacy through large-scale studies and real-world evidence. The National Medical Products Administration (NMPA) regulates clinical trials, and there is a growing number of international collaborations. China’s rapid growth is driven by a combination of government support, increased R&D spending, and a burgeoning pharmaceutical industry.

      India:

• Market Size: Approximately $15 billion.
• Overview: India is becoming a significant hub for clinical trials due to its cost advantages and large patient population. The country’s strengths include its ability to conduct large-scale studies and its growing focus on pharmacoepidemiology. The Central Drugs Standard Control Organization (CDSCO) oversees drug regulation, and India’s research landscape is supported by a range of CROs and academic institutions. The country is also experiencing increased interest from global pharmaceutical companies seeking to conduct clinical trials.

      Japan:

• Market Size: Approximately $10 billion.
• Overview: Japan is known for its advanced research infrastructure and high standards in clinical trials and drug safety studies. The Pharmaceuticals and Medical Devices Agency (PMDA) regulates clinical research, and Japan’s emphasis is on innovative therapies and precision medicine. The country’s research environment benefits from strong government support and collaboration with international pharmaceutical companies.

4. Rest of the World

      Brazil:

• Market Size: Approximately $5 billion.
• Overview: Brazil is a growing market for clinical research, driven by an expanding pharmaceutical industry and increasing research initiatives. The Brazilian Health Regulatory Agency (ANVISA) oversees clinical trials, and the country is focusing on addressing local health challenges through research. Brazil’s large population and diverse demographics make it an attractive location for clinical studies.

      South Africa:

• Market Size: Approximately $4 billion.
• Overview: South Africa is enhancing its clinical research capabilities with a focus on local health issues and disease prevalence. The South African Health Products Regulatory Authority (SAHPRA) regulates drug research, and the country is seeing growth in both local and international research activities.

      Middle East:

• Market Size: Approximately $3 billion.
• Overview: The Middle East is investing in clinical research and pharmacoepidemiology, with increasing partnerships and funding. Countries like the UAE and Saudi Arabia are expanding their research infrastructure and focusing on improving healthcare outcomes through innovative studies.

Benefits of participation

Advantages of Participating at our conference:

• As an add on advantage the Speaker & Abstract pages created in Google on your profile under your name would get worldwide visibility.

• Our robust online publicity attracts 20000+ users and 60000+ views to our Library of Abstracts which brings worldwide exposure to the researchers and speakers participate in our conferences

• All the conference participants can earn up to 16-18 CME Credits by participating at our Pharmacoepidemiology 2024 Congress scheduled as a Conference.

• To attain professional development we offer our participants a chance to earn up to 21 CPD Credits authorized by CPD Standards Office, UK by participating at our Pharmacoepidemiology 2024.

•  All the conference participants will be awarded with IOCM Certification.

•  All the conference participants will have an unique opportunity to participate at One on One Meeting with Eminent Speakers

• Top Industries Representation of Industrial Leaders, where you get a great opportunity to meet and discuss with the Industrial Leaders in person

• Thought provoking Symposia’s

•  Workshops on Carrier Development

•  Preconference workshops in all major countries

•  Nominations for Best Poster Award

•  Outstanding Young Researcher Award

•  Group Registration benefits

Benefits of Participation | Speaker

• Explore the best in Cutting edge Research

• Worldwide acknowledgment of Researcher’s profile

• Obtain professional development credits

• Your presence and talk will be recorded and hosted on YouTube and Video which in turn will gain potential value to your research profile.

• Make Lasting connections at Networking and Social Events

• We provide unique convergence of Networking, Learning and Fun into a single package

• An opportunity to give One page advertisement in abstract book and flyers distribution which eventually gets 1 Million views and add great value to your research profile

• Learn beyond your field of interest, a change to know more about the new topics and research apart from your core subject

Benefit of Participation | Sponsor

• Worlds No1 Platform to show case Pharmacoepidemiology 2024 Products

• Exposure to the international atmosphere will increase the odds of getting new business

• Opportunity to showcase the new technology, new products of your company, and/or the service your industry to a broad international audience

• Attain with an exceptional format in showcasing the products and services and to gain the potential clients for the future business prospects

• Our Pharmacoepidemiology 2024 Conference in the One and only location to reach the top customers

• Make new connections and fostering potential partnerships

• Increase your business by lead generation through our conference participants.

• Build a successful business takes a lot of time, effort and drive, so it’s always good to have a network of colleagues and associates to draw energy from people who share a similar drive and objective.

• Flip side of learning new things is relearning classic techniques. 

• Pharmacoepidemiology 2024 conferences create opportunities for greater focus and reflection that could help you take your business to the next level.

• Benchmarking key strategies for business and moving it forward

• Get answers to your business questions and challenges from credible individuals at our conference

• Exposure and Networking Opportunity with the various top decision makers of the respective organizations, will eventually grow your business in Global market

• Get to know more about your competitors are first-hand, learn more about their businesses, and discover their strengths and weaknesses, all of which can add to your business’s competitive edge.

• Encounter new vendors and suppliers for your business

• Real Benefits in New business-Many Organizations make deals and sign contracts at our Pharmacoepidemiology 2024

• We offer you the Website visibility to more than 35K visitors in less than 6 months

• Promotional logo of your organisation at our conference banner, website and other proceedings, branding and marketing material

• Hosting session slots, poster awards, recognition in opening ceremony and complimentary registrations, exhibition/workshop booth, low-budget options.

Benefit of Association for Collaborators

• No one in the world have this huge visitors towards Pharmacoepidemiology 2024, these is the best platform to show case your society.

• Promotional content and Logo of your Association at our conference banner, website and other proceedings, branding and marketing material will increase your subscribers/Members number by 20 %.

• Our Website visibility to your Organization page can give a great impact for your association in the Global Market.

• Your representatives can network with key conference delegates to update their knowledge and understanding of your organization and services.

•  Details will be added to the conference press release where the details will be shared to < 100000 outlets

•  Details will be incorporated in all conference promotional materials which will be distributed to Hospitals, Universities, Society and Researchers

Benefits of Participation | Delegate

• Helps to meet Experts & Influencers Face to Face.

• Opportunities to meet researchers and experts of same field and share new ideas

• Can help to know New Tips & Tactics

• Professional Development – Elevate your knowledge and Skills

• Conference attendance inspires, rejuvenates, and energizes delegates

• Your participation at our conference will be helpful for a new approach and ideology that can be utilized for the extending the outcome of Companies or Industries.

• Enjoy the alluring city environment where the conference is being held.

Raise your profile by being well-known

Visa application process

Visa Application Documents You should only apply for business visas to attend conferences. Contact your nearest Toronto, Canada Travel Agency/Visa Information Center/Embassy for the correct application form.

All visas for the visit to Vancouver, Canada are processed by the respective embassy authorities in the correct way only after the presentation of the corresponding documents.

If no documents are provided or if the guidelines are not followed, the competent authorities hold the right to reject/cancel the visas.

The minimum documents that may be required when applying for the visa from Toronto, Canada  include:

• Official Letter of Invitation

• Letter of Acceptance/Approval for abstracts (if you are a speaker)

• Proof of payment receipt for registration

• Hotel Booking Confirmation Letter for accommodation issued on conference letterhead

Note: For the Letter of Invitation and Accommodation Confirmation, payment of registration and accommodation fees is a prerequisite. Please contact us for more information